Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting
Title: "Future Cures for Hepatitis Delta Virus"
Summary: Update on late-stage treatments in development for HDV, including Lonafarnib, a first-in-class, oral prenylation inhibitor, and Peginterferon Lambda, a first-in-class, type III, well-tolerated interferon
Title: "Clinical Development of Lonafarnib for Hepatitis Delta Virus"
Summary: Overview of the Lonafarnib clinical development program, the first and only oral treatment in development for HDV
Title: "LIMT-2: A Phase 3 Study of 48-Week Treatment with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection"
Summary: Overview of LIMT-2 study design, rationale, sites currently activating and screening patients. First patient expected to randomize by end of 2021
"There are now multiple late-stage, promising investigational treatments in development for HDV, each with a different mechanism of action and formulation for different routes of administration," said
About Hepatitis Delta Virus (HDV)
HDV is the most severe form of human viral hepatitis. HDV occurs only as a co-infection in individuals infected with hepatitis B virus (HBV). HDV leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. It is estimated that 60% of HDV infected patients die within ten years. Approved nucleos(t)ide treatments for HBV only suppress HBV DNA, do not affect HBsAg and have no impact on HDV.
HDV is a disease with a significant impact on global health, which may affect greater than 12 million people worldwide. Globally, HDV infection is reported to be present in approximately 5% of patients with chronic HBV.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; the ability to activate sites and fully enroll the Phase 3 LIMT-2 study; the potential of Peginterferon Lambda to be an effective therapy for HDV; and the generation of clinical trial data to support its submission for regulatory approval. Various important factors could cause actual results or events to differ materially from the forward-looking statements that
Investors and Media:
Sri Ryali – CFO
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-presentations-at-upcoming-hep-dart-2021-meeting-301434870.html